Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.
about
P1343
Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid systemA novel method to identify and characterise peptide mimotopes of heat shock protein 70-associated antigens.Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection.Display technologies: application for the discovery of drug and gene delivery agents.cDNA display: a novel screening method for functional disulfide-rich peptides by solid-phase synthesis and stabilization of mRNA-protein fusions.TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases.Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions.Alternative splicing of CD200 is regulated by an exonic splicing enhancer and SF2/ASF.The rhesus rhadinovirus CD200 homologue affects immune responses and viral loads during in vivo infectionAntibody phage display libraries: contributions to oncology.Molecular mechanism of a novel CD59-binding peptide sp22 induced tumor cells apoptosis.Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapyCD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.scFv antibody: principles and clinical applicationCD200: association with cancer stem cell features and response to chemoradiation in head and neck squamous cell carcinoma.CD200 is induced by ERK and is a potential therapeutic target in melanoma.Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient processRationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression.Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemiaRadiation-Guided Peptide Delivery in a Mouse Model of Nasopharyngeal Carcinoma.Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling.Differential and tumor-specific expression of CD160 in B-cell malignancies.Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?Programmed cell removal: a new obstacle in the road to developing cancer.Targeted therapy aimed at cancer stem cells: Wilms' tumor as an example.Addressing the Inflammatory Response to Clinically Relevant Polymers by Manipulating the Host Response Using ITIM Domain-Containing Receptors.A comparison of serum miRNAs influencing metastatic growth of EMT6 vs 4THM tumor cells in wild-type and CD200R1KO mice.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice.Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cellsDiagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myelomaTranscriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia.Downstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling.Expression of selected regulatory molecules on the CD83+ monocyte-derived dendritic cells generated from patients with laryngeal cancer and their clinical significance.A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.Expression of CD200 on AML blasts directly suppresses memory T-cell function.CD200 expression in plasma cells of nonmyeloma immunoproliferative disorders: clinicopathologic features and comparison with plasma cell myeloma.
P2860
Q26865295-20A3045D-858E-423D-BF23-F6AA36291834Q33239312-1157CD0D-3023-46DF-9246-9EE7CF5243E8Q33257951-945B0C22-C0CE-44FF-A527-C4EE1158AD37Q33264491-F2934727-A7F0-44D1-8940-AD4DE02DD1CFQ33467687-9668461D-75A5-4326-B3DE-42018DE26B8EQ34061766-AA625725-70BF-45C6-BF63-0E27EFF5C4C6Q34154823-BFC76365-29C2-4DC2-A3D3-F5E0EDEDFBAFQ34246796-9BF5836D-C728-429B-A5C6-7054410329D7Q34262256-2FC6FC5D-169A-4FA3-949E-20C88A2F2C7BQ34323991-3E0A164D-496B-4CEC-970D-25E826AD59ECQ34347455-18402587-8E01-48D9-942E-89E2AFE54830Q34412294-D25CA24C-5F74-42A4-8C0E-6534AC8220AAQ34542545-3A33D834-1AE0-47BE-B5B5-AA271582F2E8Q35546950-B6F6909C-665E-4B66-A2EF-8BC62D527486Q35852647-8DDD390A-8BF9-4DB4-8DE0-5B0E6CBA8CEDQ36019782-EC32DBFA-3F95-4CC9-B3BA-8C98ABC55197Q36138007-D6B05C73-6BB0-460F-B2C4-9AB337C9B186Q36867167-726921DF-2C6E-4EE8-B29E-24F6D2CBAB79Q37032625-119361FD-D3C4-4DCE-B444-4FB6B582A699Q37046389-91E9B06E-6FC5-476E-8970-8A8FF3AA5382Q37310471-01883298-3FF5-42AE-9995-C1CE9EB09FF2Q37321696-E2B6BFFC-4614-4A69-901D-0B435F92BE32Q37625491-EDE64390-941F-4F45-83C3-75943AE04AE5Q37666618-F8D73DA5-28F0-4C70-AFB7-00F05DFB8E0FQ37967032-3DCC38A7-891C-4474-8B93-AD783DC88EF1Q38114000-02305AB6-8888-44FC-B0B9-888A14DDA78AQ38364218-45D186E1-2BBF-4E62-9842-ABEA90338305Q38433475-D6FA0510-27BE-4FF3-8CBF-14DDDF772BA3Q38636569-AE589095-8530-4652-AA83-5F62B29F92E1Q38796220-BD2D047A-10DF-469B-85BA-92A1F3CABDF3Q38911219-AB81BC66-5902-4BFA-818E-076C30394944Q39619069-392D2C89-9427-4590-BCAC-DAEC9BE343D2Q39794185-4916C791-D680-43CA-926D-6CD41342D544Q39991460-9C9B59DE-6065-4852-82A9-400A87C3C46CQ40075629-CEFD10C7-9842-477D-B4D1-6DFA2BA81E3FQ41109622-7D6B1052-BB7D-43BF-A2DD-D6A50AE69D43Q41863998-8D478422-3BF1-4190-880A-2CA3BA287E18Q42376556-DC8E05F9-BC53-48C8-A4EF-8D0287C77793Q42572899-9C1F1FAD-2559-43E2-B311-06C03DC2A6F6Q46826314-3C1C3CA1-7D0A-4927-AE2C-65D959554C5C
P2860
Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Antibodies selected from combi ...... key role in immunomodulation.
@ast
Antibodies selected from combi ...... key role in immunomodulation.
@en
type
label
Antibodies selected from combi ...... key role in immunomodulation.
@ast
Antibodies selected from combi ...... key role in immunomodulation.
@en
prefLabel
Antibodies selected from combi ...... key role in immunomodulation.
@ast
Antibodies selected from combi ...... key role in immunomodulation.
@en
P2093
P2860
P356
P1476
Antibodies selected from combi ...... key role in immunomodulation.
@en
P2093
Alan Saven
Anke Kretz-Rommel
C Ian Mockridge
E Prenn Ravey
Fenghua Qin
John R McWhirter
Katherine S Bowdish
Kathleen N Potter
Toshiaki Maruyama
P2860
P304
P356
10.1073/PNAS.0510081103
P407
P4510
P577
2006-01-17T00:00:00Z